Thalidomide for the treatment of COVID-19 pneumonia: A randomized controlled clinical trial

Thalidomide for the treatment of COVID-19 pneumonia: A randomized controlled clinical trial

Background: Coronavirus disease 2019 has become a public health concern with a high number of fatalities. Thalidomide can target inflammatory mediators and decrease inflammation in SARS-CoV-2. Materials and Methods: An open-label, randomized controlled trial was conducted on patients with compatible...

Full description

Bibliographic Details
Main Authors: Babak Amra, Farzaneh Ashrafi, Mehdi Torki, Marzieh Hashemi, Mohamad Shirzadi, Forogh Soltaninejad, Somayeh Sadeghi, Mehrzad Salmasi, Ramin Sami, Ali Darakhshandeh, Maryam Nasirian, Samaneh Pourajam
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2023-01-01
Series:Advanced Biomedical Research
Subjects:
covid-19
intensive-care unit (icu)
length of stay
pneumonia
thalidomide
Online Access:http://www.advbiores.net/article.asp?issn=2277-9175;year=2023;volume=12;issue=1;spage=14;epage=14;aulast=Amra

Internet

http://www.advbiores.net/article.asp?issn=2277-9175;year=2023;volume=12;issue=1;spage=14;epage=14;aulast=Amra

Similar Items